The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free ...

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear ...

A phase 2 trial investigated the efficacy and safety of nivolumab/ipilimumab in molecularly selected patients with mCRPC, including those with a mismatch repair deficient, high tumor mutational burden ...

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy compared with ipilimumab monotherapy.